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Abstract Focal segmental glomerulosclerosis (FSGS) is a
major cause of idiopathic steroid-resistant nephrotic syn-
drome (SRNS) and end-stage kidney disease (ESKD). In
recent years, animal models and studies of familial forms of
nephrotic syndrome helped elucidate some mechanisms of
podocyte injury and disease progression in FSGS. This
article reviews some of the experimental and clinical data






– Discuss the experimental and clinical data on the
pathophysiology of FSGS
– Review the alterations in glomerular structure and
function associated with FSGS
– To identify potential mechanisms responsible for
disease progression in FSGS
– Distinguish some targets for the future therapy of
FSGS
Focal segmental glomerulosclerosis (FSGS) is a disease
entity defined by findings on kidney biopsy [1, 2].
FSGS is the major cause of idiopathic steroid-resistant
nephrotic syndrome (SRNS) in children and adults [3].
FSGS is the most common cause of acquired chronic
renal insufficiency in children and frequently leads to
progression to end-stage kidney disease (ESKD) [2].
FSGS may occur secondary to such disparate disease
processes as HIV and obesity [1, 4]; this review focuses
on the pathophysiology of primary FSGS (i.e., with no
underlying illness).
Alterations of normal glomerular structure and function
have been found in FSGS [5]. Normal function requires that
the three major components of the glomerular filter (the
endothelial cells, podocytes, and glomerular basement
membrane) are intact and are able to provide a permse-
lective filtration barrier (Fig. 1). Specialized tight junctions
between podocyte foot processes create the slit diaphragm
which is integral to preventing the loss of protein into the
urinary space [6]. While the clinical presentation of FSGS
is often heterogeneous, a characteristic feature of the
disease is proteinuria, which implies the loss of this barrier
[2, 7]. Indeed, electron microscopy has shown distortion of
the normal architecture (or effacement) of the foot
processes of podocytes in FSGS [1]. The connection
between these projections of the epithelial cell and the
underlying basement membrane can be disrupted, leading
to the loss of nonspecific plasma proteins into the tubular
filtrate [6].
However, unlike other causes of proteinuria and ne-
phrotic syndrome, such as minimal change disease (MCD),
FSGS often progresses to ESKD. While foot process
effacement is seen in MCD as well as FSGS, histologically,
FSGS is characterized by increased extracellular matrix
within the glomerular tuft with obliteration of the glomer-
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e-mail: fkaskel@aecom.yu.eduular capillary lumen. These sclerotic lesions occur focally
and in only some segments of glomeruli, and are typically
not associated with immune complex deposition [1]. The
location of sclerotic lesions by light microscopy defines the
variants of FSGS: perihilar variant (with sclerosis of the
vascular pole), cellular variant (associated with hyper-
cellularity of the capillary space), tip variant (involving
the part of the glomerulus near the origin of the proximal
tubule), and collapsing variant (with one or more glomeruli
with global or segmental collapse) [1]. Clinically, the
variants of FSGS differ; for example, the collapsing variant
tends to progress more rapidly to ESKD and commonly
occurs in the setting of HIV [1]. It is possible that different
mechanisms may play a role in the pathogenesis of each
variant of FSGS [7, 8].
Insight into the pathogenesis of FSGS developed over
the past decade from studies of genetic mutations in mice,
models of progressive glomerulosclerosis (such as the rat
remnant kidney model), and identification of gene muta-
tions in some familial forms of nephrotic syndrome
(including congenital nephrotic syndrome and familial and
autosomal dominant FSGS) [7, 9, 10].
Key in the pathogenesis of FSGS is podocyte damage
and loss [5, 6]. Injury to podocytes occurs by four major
mechanisms: alteration of the components of the slit
diaphragm or interference with its structure, dysregulation
of the actin cytoskeleton, alteration of the glomerular
basement membrane or its interactions with the podocyte,
or alteration of the negative surface charge of the podocyte
[6, 9]. Damage to podocytes triggers apoptosis and their
detachment of podocytes from the glomerular basement
membrane [6, 9]. The ensuing reduction in podocyte
number is felt to play an important role in the pathogenesis
of FSGS [7]. The podocyte is normally a terminally
differentiated cell with limited proliferative capacity in
response to injury [7]. The initial insult to the podocyte
leads to further damage mediated by cytokine release,
mechanical stress, and further loss of polarity, resulting in
sclerosis and scarring of the glomerulus [7, 9].
Genetic mutations seen in congenital forms of nephrotic
syndrome and FSGS enabled researchers to identify
specific gene mutations involved in podocyte damage
[10]. Mutations of the nephrin gene, a podocyte-specific
transmembrane component of the slit diaphragm, are found
in congenital Finnish-type nephrotic syndrome, and may
lead to loss of normal caliber slit diaphragms [6, 9–11]. In
mouse models, mutations of nephrin-like transmembrane
genes (NEPH-1) which also localize to the slit diaphragm
result in proteinuria and early death [6, 10].
It is unclear how alteration of the slit diaphragm results
in podocyte loss. The slit diaphragm may be integral to
maintaining cell polarity or its damage may alter the
balance of cell signals, resulting in apoptosis. Mutations
in a Fyn kinase (one of the src tyrosine kinases) that
Fig. 1 A Components of the
normal glomerular filtration
barrier: (1) glomerular basement
membrane (GBM); (2) podocyte
foot process; (3) endothelial
cell; B Progressive changes seen
in focal segmental glomerulo-
sclerosis (FSGS) leading to
sclerosis: (1) foot process ef-
facement; (2) podocyte apopto-
sis/loss and exposed glomerular
basement membrane; (3) filtra-
tion of non-specific plasma pro-
teins; (4) capillary expansion;
(5) misdirected filtration at
points of synechiae; (6) forma-
tion of synechiae; (7) mesangial
matrix proliferation. Adapted
from Kwoh et al., [9]
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apoptosis resulted in proteinuria and foot process efface-
ment in a mouse model [9, 10].
Other proteins which are part of the slit diaphragm
complex include: podocin, CD2-associated protein
(CD2AP), FAT, ZO-1, P-cadherin, an LAP (leucine rich
repeat and PDZ domain) protein, and MAGI-1 [6, 10].
Mutations in podocin (a transmembrane protein that
interacts with nephrin, NEPH-1 and CD2AP) have been
identified in familial FSGS [9, 10, 12]. Recently, mutations
in CD2AP, an immunoglobulin-like protein that is involved
in nephrin integration with the podocyte cytoskeleton, have
also been linked to genetic forms of FSGS [10, 13, 14]. In
mouse models, the loss of FAT1 and FAT2 (transmembrane
proteins with cadherin-like repeats) results in the absence of
slit diaphragms, proteinuria, and early death [10]. The role
of the other components of the slit diaphragm in the
pathophysiology of FSGS is not yet clear.
Alpha-actinin-4, an important structural component of
the podocyte cytoskeleton, is mutated in some autosomal
dominant forms of FSGS [10, 15–17]. Other mutations
have been identified in association with FSGS in addition
to abnormal structural proteins. For example, TRPC6 is a
cation-selective ion-channel protein that mediates calcium
signals and has also been associated with FSGS [18].
Certain clinical variants of FSGS are suggestive of
different mechanisms of injury to the podocyte. For
example, a circulating factor which leads to glomerular
basement membrane injury has been proposed in the
pathogenesis of some types of FSGS [19, 20]. For example,
there appears to be a role of a circulatory factor in the
recurrence of FSGS in transplanted kidneys [20]. In some
patients with recurrent FSGS, proteinuria remits in response
to plasmapheresis and the removal of serum proteins. In
addition, injections of serum from patients with recurrent
FSGS were capable of inducing proteinuria in rats [20].
Another example of alternative mechanisms of injury is
collapsing FSGS, which occurs in the setting of viruses
such as HIV. In collapsing FSGS, dysregulation of the
podocyte cell cycle appears to result in immature, prolifer-
ative podocytes [21, 22]. Finally, recent work has focused
on the role of the parietal epithelial cell in the pathophys-
iology of FSGS [23]. Proliferation of parietal epithelial cells
was identified in both a transgenic model of FSGS and a
biopsy from a patient with collapsing FSGS [23].
Of great clinical importance is the mechanism by which
the initial podocyte injury progresses to the final sclerotic
lesion (Fig. 1). As podocyte numbers decline, there is a
relative exposure of the glomerular basement membrane.
Maladaptive interactions develop between the glomerular
basement membrane and the parietal epithelial cells.
Expansion of synechiae and/or the leak of protein into
Bowman’s space results in the deposition of collagen.
Ultimately, this results in the collapse of the capillary loop
and the loss of endothelial cells [5].
FactorsresultingintheprogressionofFSGStoESKDhave
also been the focus of recent research (Fig. 2). Cytokines and
vasoactive factors are believed to play a major role in the
progression of FSGS. The overexpression of transforming
growth factor β (TGFβ) or its effector proteins, the Smads,
Fig. 2 Factors involved in the progression of FSGS to end-stage
kidney disease (ESKD): initial loss or injury to podocytes (related to
defects in membrane proteins or cytoskeleton instability) leads to
cytokine release, mechanical stress, hyperfiltration, and glomerular
hypertrophy. These factors lead to upregulation of an inflammatory
response mediated by monocytes, macrophages, and T-cells. The end
result is collagen matrix deposition and fibrosis, and progression to
ESKD
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Activation of the renin-angiotensin system upregulates
TGFβ and is felt to further lead to the progression of disease
[7, 24]. Other angiogenic factors, such as platelet-derived
growth factor (PDGF) and vascular endothelial growth factor
(VEGF) may also play a role in disease progression [24].
The evidence for this is primarily based on animal models of
progressive glomerulosclerosis, such as the rat remnant
kidney model. In this model, PDGF and VEGF are
upregulated and the later loss of VEGF expression correlates
with progression of the glomerulosclerosis [24, 25].
Mechanical stress is also believed to play a role in the
progression of FSGS [9, 26]. Increased filtration due the
defects of the filtration barrier results in increased single-
nephron glomerular filtration rate (SNGFR). This
hyperfiltration results in hypertrophy of glomeruli. The
hypertrophy exacerbates the mismatch between the glomer-
ular basement membrane and the decreased numbers of
podocytes, resulting in further injury [9].
Another factor in the progression of FSGS is tubuloin-
terstitial injury. Clinically, tubulointerstitial injury is a
predictor of the loss of renal function in FSGS [1, 27].
The nonspecific entry of proteins into the tubular lumen is
one potential source of damage to the interstitium. Indeed,
persistence of nephrotic-range proteinuria is a negative
prognostic factor for the progression of FSGS to ESKD
[28]. While it is unclear if proteinuria itself is toxic to the
tubulointerstitium, decreases in proteinuria achieved by
angiotensin-converting enzyme (ACE) inhibitors and by
angiotensin receptor blockers (ARB) appear to slow disease
progression in some adults with FSGS [9, 29].
The presence of plasma proteins in the tubular filtrate may
directly injure the tubulointerstitium. Cytokines (such as
TGFβ), when present in the tubules, will recruit monocytes,
macrophage, and T-cells. This stimulates other cytokines,
including interleukin-1, tumor necrosis factor alpha, and other
chemokines [24]. The inflammatory infiltrate leads to
mesangial matrix deposition, promoting the collapse of
glomeruli. The cellular infiltrate and cytokines also damage
tubular epithelial cells, and some tubular epithelial cells may
undergo transformation to mesenchymal cells (an epithelial-
mesenchymal transition or EMT) [24]. These mesenchymal
cells, as well as recruited and stimulated fibroblasts, result in
collagen matrix deposition and tubulointerstitial fibrosis [24].
The beneficial effects of blocking the renin-angiotensin
system may not be limited to their antiproteinuric or
antihypertensive effects. As noted earlier, angiotensin
stimulates TGFβ, contributing to fibrosis. It can also induce
oxidative stress and it is stimulated by mechanical stress,
such as hyperfiltration [24]. In addition, angiotensin affects
intracellular calcium concentrations and the podocyte
cytoskeleton [24]. Inhibition of angiotensin may slow
progression by these local mechanisms [9, 29].
With the increasing incidence of FSGS in children [30],
these pathways of podocyte injury and disease progression
provide important targets for future intervention. Trials
have already been initiated to antagonize cytokines, such as
TGFβ. Future therapeutic targets may include factors
involved in podocyte protection or tubulointerstitial injury.
Questions
(Answers appear following the reference list)
1. Which of the following statements is TRUE regarding
the current understanding of the pathogenesis of focal
segmental glomerulosclerosis (FSGS)?
a. FSGS may result from immune-complex-mediated
damage to endothelial cells
b. Alterations in components of the slit diaphragm
may play a role in the pathogenesis of FSGS
c. Proliferation of podocytes leads to cytokine release
and mechanical stress, resulting in scarring and
sclerosis of the glomeruli
d. Mutations in a chloride channel have been associ-
ated with FSGS and may be pathogenic
2. All ofthe following are mutations of structural proteinsthat
have been identified as pathogenic in FSGS EXCEPT:




3. Progression of FSGS to end-stage kidney disease
(ESKD) results from:
a. Downregulationof transforminggrowth factor β(TGFβ)
b. Decreased glomerular filtration
c. Tubulointerstitial injury
d. Blockade of the renin-angiotensin system
4. Proteinuria in the setting of FSGS:
a. Has no effect on clinical course
b. May be decreased by treatment with angiotensin-
converting enzyme (ACE) inhibitors
c. Results from an increased number of glomerular
foot processes
d. Leads to the loss of mesangial matrix
5. Which of the following is FALSE:
a. A circulating factor may play a role in the
pathogenesis of FSGS
b. Proliferation of parietal epithelial cells has been
identified in collapsing FSGS
Pediatr Nephrol (2007) 22:350–354 353c. Podocyte loss due to necrosis appears to play a role
in the pathogenesis of FSGS
d. CD2-associated protein, FAT, nephrin, and podocin
are examples of slit diaphragm proteins
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